Climb Bio Inc Share Price

NASDAQ: CLYM

Small Cap

$2.05

-0.20

(-8.89%)

as on September 16, 2025 at 1:29 am IST

$₹

Climb Bio Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

Day's Low
Day's High
$2.03
Day's Price Range
$2.29
$2.05
0.98%
Downside
11.71%
Upside
52 Week's Low
52 Week's High
$1.05
52-Week Price Range
$5.86
$2.05
48.78%
Downside
185.85%
Upside

Climb Bio Inc share price movements today

Previous Close: $2.25
Open: $2.26
Volume: 1.2M
Day's Low - High: $2.03 - $2.29
52 Week Low - High: $1.05 - $5.86

Climb Bio Inc Historical Returns

1 Month Return: + 18.42 %
3 Month Return: + 78.57 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Climb Bio Inc Stock Fundamentals & Key Indicators

Check Climb Bio Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$152.5M

EPS (TTM)

-0.7425

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

4136600.00%

Climb Bio Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Climb Bio Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Climb Bio Inc	NA	$152.5M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Climb Bio Inc Stock's Interest Amongst Investors

Search interest for Climb Bio Inc Stock has decreased by -70% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 17, 2025 to September 16, 2025

Change:-70% versus previous 30 day period

Climb Bio Inc Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	0
Operating Income	-6	-5	-5	-3	-56	-11	-10	-23	-10
EBITDA	-6	-5	-5	-3	-56	-11	-10	-23	-8
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-
Income Before Tax	-5	-3	-3	-1	-54	-8	-8	-20	-8
Income Tax Expense	-	-	-	-	-	-	-	-	-
Net Income	-5	-3	-3	-1	-54	-8	-8	-20	-8
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Climb Bio Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Income	-20	-35	-45	-40	-82
EBITDA	-11	-35	-45	-40	-30
Interest Expense	-	-	-	-	-
Depreciation	-	-	-	-	-
Income Before Tax	-20	-47	-45	-35	-73
Income Tax Expense	-	-	-	-	-
Net Income	-20	-47	-45	-35	-73
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Climb Bio Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-5	-3	-3	-1	-54	-8	-8	-20	-8
Operating Cash Flow	-7	3	0	-1	0	-7	-5	-15	-11
Investing Cash Flow	-1	28	36	13	-9	-71	-53	-42	4
Financing Cash Flow	0	0	0	0	128	2	0	-	-
Change in Cash	-9	32	35	11	118	-76	-58	-58	-6

Climb Bio Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-20	-47	-45	-35	-73
Operating Cash Flow	-14	-36	-37	-20	-15
Investing Cash Flow	8	-114	34	68	-121
Financing Cash Flow	4	177	-	0	130
Change in Cash	0	26	-3	49	-5

Insights on Climb Bio Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 118.7% return, outperforming this stock by 150.1%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 145.0%
NEGATIVE IMPACT
Price Dip
In the last 7 days, CLYM stock has moved down by -5.5%

About Climb Bio Inc

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Organisation	Climb Bio Inc
Headquarters	20 William Street, Wellesley Hills, MA, United States, 02481
CEO	Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
E-voting on shares	Click here to vote

Key Management of Climb Bio Inc

Name	Title
Dr. Edgar D. Charles M.D., M.Sc.	Chief Medical Officer
Ms. Cindy J. Driscoll M.B.A.	Senior Vice President of Finance
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc	Interim Principal Financial Officer, CEO, President & Director
Ms. Chandra Adams J.D.	VP & General Counsel
Dr. Nishi Rampal M.D.	Senior Vice President of Clinical Development
Ms. Janaki M. Subramanyam M.Sc.	VP & Head of Regulatory Affairs
Ms. Kate Hecht M.B.A.	Senior Vice President of Program Management
Dr. Perrin Wilson B.S., Ph.D.	Chief Business Officer

FAQs

What is Climb Bio Inc share price today?

Climb Bio Inc share price today is $2.05 as on September 16, 2025 at 1:29 am IST at the close of the market. Climb Bio Inc share today touched a day high of $2.29 and a low of $2.03.

What is the 52 week high and 52 week low for Climb Bio Inc share?

Climb Bio Inc share touched a 52 week high of $5.86 on October 3, 2024 and a 52 week low of $1.05 on April 7, 2025. Climb Bio Inc stock price today i.e. September 16, 2025 at 1:29 am IST is closed at $2.05,which is 65.02% down from its 52 week high and 95.24% up from its 52 week low.

What is Climb Bio Inc's market capitalisation today?

Climb Bio Inc market capitalisation is $0.00T as on September 16, 2025 at 1:29 am IST.

How to invest in Climb Bio Inc Stock (CLYM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Climb Bio Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Climb Bio Inc Shares that will get you 0.7317 shares as per Climb Bio Inc share price of $2.05 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Climb Bio Inc Stock (CLYM) from India?

Indian investors can start investing in Climb Bio Inc (CLYM) shares with as little as ₹88.141 or $1 (as of September 16, 2025 at 11:36 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Climb Bio Inc stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 11:36 am IST). Based on Climb Bio Inc share’s latest price of $2.05 as on September 16, 2025 at 1:29 am IST, you will get 4.8780 shares of Climb Bio Inc. Learn more about fractional shares .